Follow The Short Interest: Could Sensus Healthcare Incorporated (NASDAQ:SRTS) See a Reversal After More Sellers Came In?

November 16, 2016 - By Clifton Ray   ·   0 Comments

Follow The Short Interest: Could Sensus Healthcare Incorporated (NASDAQ:SRTS) See a Reversal After More Sellers Came In?

The stock of Sensus Healthcare Incorporated (NASDAQ:SRTS) registered an increase of 0.32% in short interest. SRTS’s total short interest was 62,800 shares in November as published by FINRA. Its up 0.32% from 62,600 shares, reported previously. With 1,200 shares average volume, it will take short sellers 52 days to cover their SRTS’s short positions. The short interest to Sensus Healthcare Incorporated’s float is 0.79%. About 8,300 shares traded hands or 1062.46% up from the average. Sensus Healthcare Inc (NASDAQ:SRTS) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.

Sensus Healthcare, Inc. is a medical device firm specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The company has a market cap of $74.38 million. The Company’s products treat Basal Cell Carcinoma, Squamous Cell Carcinoma, Kaposi’s Sarcoma, Metatyptic Carcinoma, Cutaneous Appendage Carcinoma and other primary malignant epithelial neoplasms of the skin. It currently has negative earnings. The Company’s products also treat keloids, which are disfiguring, often benign, and tumors, which are more common in people with skin of color.

SRTS Company Profile

Sensus Healthcare, Inc. is a medical device firm specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The Company’s products treat Basal Cell Carcinoma, Squamous Cell Carcinoma, Kaposi’s Sarcoma, Metatyptic Carcinoma, Cutaneous Appendage Carcinoma and other primary malignant epithelial neoplasms of the skin. The Company’s products also treat keloids, which are disfiguring, often benign, and tumors, and are more common in people with skin of color. The Firm offers various solutions, including SRT-100, SRT-100 Vision, SRT-100 Lynx, skin cancer treatment and keloid removal.

More notable recent Sensus Healthcare Inc (NASDAQ:SRTS) news were published by: Prnewswire.com which released: “Sensus Healthcare, Inc. Units Separate; Trading of Common Stock and Warrants …” on July 25, 2016, also Prnewswire.com with their article: “Sensus Healthcare, Inc. Announces Separation of Units Sold in IPO” published on July 21, 2016, Prnewswire.com published: “Sensus Healthcare to Participate in Two Upcoming Investor Conferences on …” on November 16, 2016. More interesting news about Sensus Healthcare Inc (NASDAQ:SRTS) were released by: Prnewswire.com and their article: “Sensus Healthcare, Inc. Prices Initial Public Offering” published on June 02, 2016 as well as Prnewswire.com‘s news article titled: “Sensus Healthcare Reports Second Quarter 2016 Results” with publication date: August 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>